Navigation Links
10,000 New Jobs, Investments Increased
Date:5/12/2009

FRANKFURT, Germany, May 12 /PRNewswire/ --

- German Chemical Parks Record Growth - Attractive Business Model for Investors

The number of employees in German chemical parks has increased by roughly 10,000 to 240,000 between 2006 and 2008. In this same period, the number of companies doing business at these sites increased from 840 to 920. These figures were presented today by Dr. Klaus-Dieter Juszak, Chairman of the German Sector Group of Chemical Parks and Sites in the German Chemical Industry Association (VCI). These figures, based on a new industry estimate, were presented during a press conference at the ACHEMA 2009 in Frankfurt. "The German concept of chemical parks is successful and has a promising future," noted Juszak. Michael Pfeiffer, Chief Executive of Germany Trade & Invest (GTAI), confirmed the interest of foreign companies in the successful business model provided by chemical parks.

Establishment of Value-Added Chains

Investments in chemical parks have increased. In 2008 the total investment volume surpassed EUR 3.5 billion for the first time. In the years leading up to 2008, companies invested an average of roughly EUR 3 billion in the expansion and construction of facilities. More than 80 percent of investment expenditures in the industry fell upon chemical producers. These investments include both new and established companies. Chemical parks create an optimal environment, for new and established companies alike.

Efficiency through Network Structures

For investors looking to Germany as a chemical production site, Germany offers numerous location advantages over its international competitors: a reliable energy supply, combined production potential, and the sharing of costs for raw materials and intermediate goods.

Research Network

The unique network of university and independent research institutes is a further advantage for Germany as a chemical industry site: Every second chemical park, according to Juszak, is directly connected to a research network, as the industry is dependent on a constant flow of research results. The chemical industry also hopes to continue its high research and development investments in order to emerge stronger from the global economic crisis. In this context, Juszak welcomes the federal minister's introduction of tax relief for companies' research and development initiatives. "It is important that both the small businesses and large companies benefit from this support," stressed the Chairman, "because innovation, especially in the chemical industry, is based heavily on cooperation."

GTAI Chief Executive Michael Pfeiffer confirms that Germany is also seen as an attractive investment location for foreign investors. Germany Trade & Invest is the new foreign trade and inward investment promotion agency of the Federal Republic of Germany. One of the organization's missions is to attract foreign investors to Germany. According to Pfeiffer, Germany scores very highly in terms of the country's competitiveness as an investment location. This is true not only for the chemical industry and its related industries, but also extends to other branches. In a recently published study by the American Chamber of Commerce (AmCham), US companies ranked Germany as the most attractive business location in Europe. Reasons cited included the high product and process quality in Germany. These are factors that both companies and customers greatly value, especially in an economic downturn. Pfeiffer further discussed current industry figures. According to these figures, Germany's chemical industry is number one in Europe in terms of revenues, exports, investment, and R&D expenditures. "The German chemical and chemical processing industry is one of the global heavyweights. Germany is a clear leader in terms of exports. Chemical companies that produce in Germany can come out ahead of the competition in international markets," said Pfeiffer.

In addition to investments by the chemical industry and the related processing industries, companies in renewable energies are increasingly seeking proximity to chemical parks, especially in photovoltaics, biopolymers, and biofuels. This demand is notably visible in R&D-intensive investment projects.

Kontakt: VCI-Pressestelle, Telefon: +49(0)69-2556-1496, E-Mail: zedlitz@vci.de

Kontakt: GTAI-Pressestelle, Telefon: +49(0)30-200-099-173, E-Mail: eva.henkel@gtai.com


'/>"/>
SOURCE Germany Trade and Invest GmbH
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
2. American Telugu Association's Convention Attracts Over 10,000 People in the U.S.
3. Win a $10,000 Education Fund for Your Miracle Child
4. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
5. Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
6. Voler Systems Continues Investments and Expands Services
7. Experts at Healthcare Conference Support Investments in the Health of Work Culture and Care Processes, Not Just Technology
8. ZINO Society Spurring Investments, 12 Life Sciences Companies to Vie for $50,000 ZINO Life Fund
9. Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts
10. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
11. Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/15/2017)... (PRWEB) , ... February 15, 2017 , ... ... Posard, as President and Chief Commercial Officer with GenePeeks. Matt is a ... , GenePeeks is a computational genomics company focused on identifying inherited disease risk ...
(Date:2/15/2017)... WASHINGTON, Feb. 15, 2017  Vanda Pharmaceuticals Inc. ... results for the fourth quarter and full year ... an exceptional year for Vanda as we continued ... and secured long-term exclusivity for Fanapt," said Mihael ... addition, our emerging pipeline with important 2017 milestones ...
(Date:2/15/2017)... ... February 15, 2017 , ... Diameter Health (Diameter) ... Health technology in the hands of Lantana analysts. The high-performance platform of Diameter ... public health entities – all those mining value from clinical data – to ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/25/2017)... , Jan. 25, 2017 The Elements ... Management (IAM) lifecycle is comprised of a comprehensive ... the purpose of maintaining digital identities and providing ... and applications. There are significant number of programs ... time to time by optimizing processes and changing ...
Breaking Biology News(10 mins):